Polivy (polatuzumab vedotin)

pCPA File Number: 22584
Negotiation Status:
Under consideration for negotiation
Indication(s):
Polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of adult patients with previously untreated large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), high grade B-cell lymphoma, Epstein-Barr virus-positive (EBV+) DLBCL NOS, and T-cell/histiocyte rich LBCL.
Sponsor/Manufacturer:
HOFFMANN-LA ROCHE LIMITED
CDA-AMC Project Number:
PC0313-000
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded:
Not Applicable